Published Guidance, NICE advice and quality standards

Skip to filters Skip to results

Showing 676 to 700 of 756

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer	TA208	24 November 2010	24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours	TA209	24 November 2010	24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours	TA86	27 October 2004	1 November 2010
Denosumab for the prevention of osteoporotic fractures in postmenopausal women	TA204	27 October 2010	27 October 2010
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)	TA206	27 October 2010	27 October 2010
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)	TA207	27 October 2010	27 October 2010
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C	TA200	22 September 2010	22 September 2010
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	TA195	25 August 2010	25 August 2010
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis	TA199	25 August 2010	25 August 2010
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia	TA193	28 July 2010	28 July 2010
Capecitabine for the treatment of advanced gastric cancer	TA191	28 July 2010	28 July 2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer	TA192	28 July 2010	28 July 2010
Human growth hormone (somatropin) for the treatment of growth failure in children	TA188	26 May 2010	26 May 2010
Infliximab and adalimumab for the treatment of Crohn's disease	TA187	19 May 2010	19 May 2010
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes	TA47	5 September 2002	1 March 2010
Topotecan for the treatment of relapsed small-cell lung cancer	TA184	25 November 2009	25 November 2009
Topotecan for the treatment of recurrent and stage IVB cervical cancer	TA183	28 October 2009	28 October 2009
Guidance on the use of electroconvulsive therapy	TA59	26 April 2003	1 October 2009
Sunitinib for the treatment of gastrointestinal stromal tumours	TA179	23 September 2009	23 September 2009
Pemetrexed for the first-line treatment of non-small-cell lung cancer	TA181	23 September 2009	23 September 2009
Alitretinoin for the treatment of severe chronic hand eczema	TA177	26 August 2009	26 August 2009
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma	TA178	26 August 2009	26 August 2009
Tenofovir disoproxil for the treatment of chronic hepatitis B	TA173	22 July 2009	22 July 2009
Rituximab for the first-line treatment of chronic lymphocytic leukaemia	TA174	22 July 2009	22 July 2009
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults	TA170	22 April 2009	22 April 2009

Results per page

10
25
50
All